Xilio Therapeutics Ownership | Who Owns Xilio Therapeutics?


OverviewRevenueFinancialsChart

Xilio Therapeutics Ownership Summary


Xilio Therapeutics is owned by 14.06% institutional investors, 35.34% insiders, and 50.60% retail investors. Gilead sciences is the largest institutional shareholder, holding 6.32% of XLO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 0.99% of its assets in Xilio Therapeutics shares.

XLO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockXilio Therapeutics14.06%35.34%50.60%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Gilead sciences9.11M6.32%$5.83M
Rivervest venture management1.44M5.16%$1.37M
Bain capital life sciences investors4.57M4.74%$3.85M
Merck1.48M1.54%$1.25M
Takeda pharmaceutical1.48M1.53%$1.24M
Vanguard group1.26M0.87%$803.64K
Empery asset management, lp1.18M0.82%$757.38M
Morgan stanley839.85K0.58%$537.67K
Fmr511.82K0.53%$431.31K
Aju ib investment667.74K0.46%$427.49K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Rivervest venture management1.44M20.01%$1.37M
Takeda pharmaceutical1.48M7.59%$1.24M
Aju ib investment667.74K1.88%$427.49K
Empery asset management, lp1.18M0.67%$757.38M
Merck1.48M0.55%$1.25M
Gilead sciences9.11M0.30%$5.83M
Bain capital life sciences investors4.57M0.26%$3.85M
Gsa capital partners llp147.97K0.01%$95.00K
Two sigma securities32.13K0.00%$27.08K
Xtx topco76.05K0.00%$64.08K

Top Buyers

HolderShares% AssetsChange
Empery asset management, lp1.18M0.67%1.18M
Gsa capital partners llp147.97K0.01%147.97K
Renaissance344.42K0.00%139.72K
State street163.89K-120.50K
Susquehanna group, llp49.09K-49.09K

Top Sellers

HolderShares% AssetsChange
Rock springs capital management lp---3.00M
Ghisallo capital management---1.33M
Atlas venture life science advisors---992.91K
Squarepoint ops---328.79K
Trustees of columbia university in the city of new york---249.63K

New Positions

HolderShares% AssetsChangeValue
Empery asset management, lp1.18M0.67%1.18M$757.38M
Gsa capital partners llp147.97K0.01%147.97K$95.00K
Susquehanna group, llp49.09K-49.09K$46.88K
Jane street group42.08K-42.08K$26.94K
Raymond james & associates38.83K-38.83K$36.79K

Sold Out

HolderChange
Qube research-4.00
Jpmorgan chase-62.00
Wells fargo & company/mn-108.00
Citigroup-258.00
Royal bank of canada-533.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202522-38.89%20,254,500-8.15%142.69%8-27.27%3-
Sep 30, 2025365.88%22,051,916-1.34%222.55%1110.00%3-72.73%
Jun 30, 2025343.03%23,770,26321.47%314.64%11-21.43%1042.86%
Mar 31, 202535-22,528,206-12.87%301.82%14-6.67%716.67%
Dec 31, 202417-48.48%13,981,677-12.36%223.49%5-64.29%4-

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv723.75K0.99%-
Vanguard Institutional Extnd Mkt Idx Tr367.82K0.50%-
Fidelity Extended Market Index142.90K0.19%-275.00
iShares Micro-Cap ETF59.99K0.12%-
Fidelity Total Market Index63.21K0.09%-
Bridgeway Ultra-Small Company Market56.08K0.08%-
Fidelity Series Total Market Index49.58K0.07%-
Spartan Extended Market Index Pool E30.66K0.06%1.54K
Spartan Extended Market Index Pool F37.39K0.05%275.00
NT Ext Equity Mkt Idx Fd - NL34.73K0.05%-

Recent Insider Transactions


DateNameRoleActivityValue
Feb 13, 2026GILEAD SCIENCES, INC.-Buy$373.90
Jan 02, 2026Brennan Kevin M. SVP, FINANCE AND ACCOUNTINGSell$1.17K
Jan 02, 2026Frankenfield Christopher James Chief Financial OfficerSell$4.52K
Jun 17, 2025Shannon James Samuel-Buy$17.21K
Jun 16, 2025Shannon James Samuel-Buy$30.87K

Insider Transactions Trends


DateBuySell
2025 Q27-
2025 Q1-2
2024 Q42-
2024 Q3--
2024 Q22-

XLO Ownership FAQ


Who Owns Xilio Therapeutics?

Xilio Therapeutics shareholders are primarily institutional investors at 14.06%, followed by 35.34% insiders and 50.60% retail investors. The average institutional ownership in Xilio Therapeutics's industry, Biotech Stocks , is 381.47%, which Xilio Therapeutics falls below.

Who owns the most shares of Xilio Therapeutics?

Xilio Therapeutics’s largest shareholders are Gilead sciences (9.11M shares, 6.32%), Rivervest venture management (1.44M shares, 5.16%), and Bain capital life sciences investors (4.57M shares, 4.74%). Together, they hold 16.22% of Xilio Therapeutics’s total shares outstanding.

Does Blackrock own Xilio Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Xilio Therapeutics.

Who is Xilio Therapeutics’s biggest shareholder by percentage of total assets invested?

Rivervest venture management is Xilio Therapeutics’s biggest shareholder by percentage of total assets invested, with 20.01% of its assets in 1.44M Xilio Therapeutics shares, valued at 1.37M$.

Who is the top mutual fund holder of Xilio Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Xilio Therapeutics shares, with 0.99% of its total shares outstanding invested in 723.74K Xilio Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools